Your browser is no longer supported. Please, upgrade your browser.
AZN [NASD]
AstraZeneca PLC
Index- P/E42.42 EPS (ttm)1.22 Insider Own0.50% Shs Outstand2.62B Perf Week4.47%
Market Cap136.19B Forward P/E15.96 EPS next Y3.23 Insider Trans0.00% Shs Float2.60B Perf Month4.66%
Income3.20B PEG2.22 EPS next Q0.75 Inst Own15.70% Short Float3.79% Perf Quarter0.56%
Sales26.62B P/S5.12 EPS this Y137.20% Inst Trans-6.38% Short Ratio9.00 Perf Half Y-1.75%
Book/sh5.95 P/B8.68 EPS next Y53.46% ROA5.20% Target Price63.60 Perf Year3.20%
Cash/sh3.03 P/C17.04 EPS next 5Y19.10% ROE25.10% 52W Range46.48 - 64.94 Perf YTD3.28%
Dividend1.40 P/FCF512.00 EPS past 5Y1.70% ROI12.20% 52W High-19.62% Beta0.56
Dividend %2.71% Quick Ratio0.80 Sales past 5Y1.50% Gross Margin80.00% 52W Low12.31% ATR0.91
Employees76100 Current Ratio1.00 Sales Q/Q11.20% Oper. Margin19.40% RSI (14)63.83 Volatility1.14% 1.32%
OptionableYes Debt/Eq1.30 EPS Q/Q223.30% Profit Margin12.00% Rel Volume1.66 Prev Close51.63
ShortableYes LT Debt/Eq1.15 EarningsApr 30 BMO Payout112.50% Avg Volume10.95M Price52.20
Recom1.50 SMA204.61% SMA505.17% SMA200-1.13% Volume3,295,038 Change1.10%
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Apr-20-21 09:23AM  
08:02AM  
07:50AM  
04:01AM  
Apr-19-21 08:31PM  
08:00PM  
05:00PM  
01:49PM  
01:06PM  
12:29PM  
12:22PM  
11:36AM  
10:09AM  
10:05AM  
09:57AM  
08:10AM  
07:58AM  
07:53AM  
07:45AM  
06:42AM  
05:40AM  
05:40AM  
05:00AM  
04:58AM  
03:50AM  
01:28AM  
Apr-18-21 10:48AM  
09:00AM  
Apr-17-21 09:13AM  
08:42AM  
08:23AM  
Apr-16-21 04:08PM  
03:45PM  
02:57PM  
02:07PM  
01:53PM  
11:44AM  
11:22AM  
10:25AM  
09:23AM  
08:48AM  
07:53AM  
07:35AM  
07:17AM  
06:53AM  
06:51AM  
06:30AM  
Apr-15-21 03:47PM  
03:41PM  
03:13PM  
02:04PM  
01:42PM  
10:27AM  
10:09AM  
09:37AM  
09:28AM  
08:48AM  
07:39AM  
07:15AM  
06:51AM  
06:05AM  
Apr-14-21 08:00PM  
05:36PM  
03:51PM  
03:44PM  
03:08PM  
02:46PM  
02:11PM  
01:43PM  
01:15PM  
11:57AM  
11:54AM  
11:21AM  
11:19AM  
11:16AM  
11:08AM  
11:02AM  
11:02AM  
10:50AM  
10:46AM  
10:39AM  
10:37AM  
10:23AM  
10:11AM  
09:40AM  
08:54AM  
08:17AM  
06:50AM  
06:47AM  
06:38AM  
06:28AM  
05:52AM  
05:35AM  
04:02AM  
02:58AM  
01:48AM  
Apr-13-21 11:37PM  
08:00PM  
08:00PM  
08:00PM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; and Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.